Literature DB >> 15482950

Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists.

Paul A Tuthill1, Pamela R Seida, William Barker, Joel A Cassel, Serge Belanger, Robert N DeHaven, Michael Koblish, Susan L Gottshall, Patrick J Little, Diane L DeHaven-Hudkins, Roland E Dolle.   

Abstract

A new class of kappa-opioid receptor agonists is described. The design of these agents was based upon energy minimization and structural overlay studies of the generic azepin-2-one structure 3 with the crystal structure of arylacetamide kappa agonist 1, ICI 199441. The most active compound identified was ligand 4a (K(i)=0.34 nM), which demonstrated potent antinociceptive activity after oral administration in rodents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482950     DOI: 10.1016/j.bmcl.2004.08.041

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Chemical function-based pharmacophore generation of selective kappa-opioid receptor agonists by catalyst and phase.

Authors:  Jing Zhang; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2009-02-11       Impact factor: 1.810

Review 2.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

3.  Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity.

Authors:  Dean G Brown; Peter R Bernstein; Ye Wu; Rebecca A Urbanek; Christopher W Becker; Scott R Throner; Bruce T Dembofsky; Gary B Steelman; Lois A Lazor; Clay W Scott; Michael W Wood; Steven S Wesolowski; David A Nugiel; Stephanie Koch; Jian Yu; Donald E Pivonka; Shuang Li; Carol Thompson; Anna Zacco; Charles S Elmore; Patricia Schroeder; JianWei Liu; Christopher A Hurley; Stuart Ward; Hazel J Hunt; Karen Williams; Joseph McLaughlin; Valerie Hoesch; Simon Sydserff; Donna Maier; David Aharony
Journal:  ACS Med Chem Lett       Date:  2012-11-12       Impact factor: 4.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.